¹Sh. K. Yusupova, ²Z. Yu. Halimova, ³M.A. Khuzhamberdiev

¹Associate Professor, Ph.D., Head of the Department of Hospital therapy and Endocrinology, Andijan State Medical Institute

²Doctor of Medical Sciences, Head of the Department of Neuroendocrinology with pituitary surgery of the Republican Specialized Scientific and Practical Medical Center of the Ministry of Health of the Republic of Uzbekistan named after Academician E.H. Turakulov

³Professor, DSc., Head of the Department, Faculty of Therapy, Andijan State Medical Institute

The aim of the study was to study the relationship between aldosterone and the degree of obesity in patients with type 2 diabetes associated with chronic heart failure.The features of metabolic and hormonal disorders were studied in 65 patients with DM2 and CHF, including 29 women and 36 men.The patients were subjected to anthropometric studies (OT, OB, OT/OB, BMI). The interpretation of BMI indicators was carried out in accordance with WHO recommendations. In the studied groups of subjects, lipid fluctuations varied from normal values to their significant deviations in group 3 of patients with grade 2 obesity.The main physiological effects of aldosterone that are important in CHF are 1) sodium and fluid retention (activation of renal aldosterone receptors); 2) activation of aldosterone-dependent; 3) increased excretion of potassium and magnesium; 4) delayed excretion of norepinephrine.So, our results confirm the results of these studies and require further study.In 54.5% of patients with DM2 and CHF with obesity of the 1st degree and 81.8% of patients with obesity of the 2nd degree, an increased level of plasma aldosterone is determined, accompanied by an increased content of renin, p < 0.05

Type 2 diabetes mellitus, chronic heart failure, hormones.

1) Bogdanov A.R., Derbeneva S.A., Chernyak O. O7., A.A. Bogdanovaidr. Genetic predictors of chronic heart failure in obese patients // Obesity and metabolism. 2019; 16 (1): 39-46 doi: https://doi.org/10.14341/omet9667 Obesityandmetabolism. 2019; 16 (1): 39-46

2) Berezikova E.N. Clinical-genetic and neurohormonal mechanisms of ischemic remodeling, myocardial apoptosis and heart failure: an innovative strategy for personalized diagnosis, prevention and treatment. Dissertation for the degree of Doctor of Medical Sciences. sciences. - Tomsk; 2014. (InRuss.)] Available at: http://docplayer.ru/43228271- Berezikova-ekaterinanikolaevna.html. Link active on 04/07/2019

3) Bernardi S, Michelli A, Zuolo G, et al. Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease. // J Diabetes Res. 2016; 2016: 8917578.doi: 10.1155 / 2016/8917578.

4) Arutyunov G.P. CHF therapy. Is the choice of the first drug always deterministic? // Russian medical journal. - 2006. – T.14. - No. 2. - C.137-142.

5) Dei Cas A, Khan SS, Butler J, Mentz RJ, A et al. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC. // Heart failure. 2015; 3 (2): 136– 45. DOI: 10.1016 / j.jchf.2014.08.004

6) Vogt B, Bochud M, Burnier M. The Association of Aldosterone With Obesity-Related Hypertension and the Metabolic Syndrome. SeminNephrol. 2007; 27 (5): 529-537. doi: 10.1016 / j.semnephrol.2007.07.009

7) Bogdanov A.R. Derbeneva S.A.,. Golubeva A. And Aldosterone is a possible predictor of heart failure in obese patients? // Medical portal for doctors. https: //umedp.ru/articles/aldosteron_vozmozhnyy_prediktor_serdechnoy_nedostatochnosti_u_bolnykh_ozhireniem.html

8) Vatutin N. T., Shevelyok A. Influence of comorbid conditions on the blood aldosterone level in patients with CHF with preserved left ventricular systolic function // https://doi.org/10.15829/1728-8800-2017-6-92-98

VOLUME 04 ISSUE 12 December 2021